CytomX Therapeutics Receives $70,000,000 Series D Financing

  • Feed Type
  • Date
    6/17/2015
  • Company Name
    CytomX Therapeutics
  • Mailing Address
    343 Oyster Point Blvd. South San Francisco, CA 94080 USA
  • Company Description
    CytomX Therapeutics is an early stage, privately-funded biotechnology company developing Probodies, proteolytically-activated antibodies.
  • Website
    http://www.cytomx.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $70,000,000
  • Transaction Round
    Series D
  • Proceeds Purposes
    Proceeds from the financing will support the continued advancement of CytomX’s pipeline of Probody therapeutics toward clinical studies, including a Precision cancer immunotherapy directed against PD-L1 and Probody drug conjugates against novel, first in class targets. The financing will also support the expansion of Probody research and development activities in the areas of T-cell agonists, bispecific antibodies and engineered T-cell therapies.
  • M&A Terms
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor

Trending on Xconomy